Lexicon Pharmaceuticals | LXRX - Ordinary Share Capital


Lexicon Pharmaceuticals reported $363.47M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Abbott USD 1.74B 2.94M Mar/2026
Acadia Pharmaceuticals USD 172.31M 174K Sep/2026
Agios Pharmaceuticals USD 59.6M 264K Jun/2026
Akebia Therapeutics USD 265.42M 199K Dec/2025
Alnylam Pharmaceuticals USD 133.88M 141K Sep/2026
AstraZeneca USD 1.55B 28K Sep/2026
BioMarin Pharmaceutical USD 193.68M 141K Sep/2026
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Halozyme Therapeutics USD 113.94M 106K Sep/2026
Illumina USD 151.3M 607K Jun/2026
Insmed USD 218.28M 1.76M Jun/2026
Ironwood Pharmaceuticals USD 160K 0 Dec/2024
J&J USD 2.41B 1.64M Jun/2026
Lexicon Pharmaceuticals USD 363.47M 67K Dec/2025
MacroGenics USD 63.65M 86K Jun/2026
MannKind USD 321.63M 11.72M Sep/2026
Merck USD 2.47B 1.05M Jun/2026
Moderna USD 391M 2M Sep/2025
Novartis USD 1.89B 12.09M Sep/2026
PTC Therapeutics USD 83.33M 445K Jun/2026
Puma Biotechnology USD 5K 0 Jun/2024
Sarepta Therapeutics USD 107.23M 1.61M Sep/2026
Thermo Fisher Scientific USD 369.75M 1.88M Sep/2026
Ultragenyx Pharmaceutical USD 98.6M 300K Jun/2026
United Therapeutics USD 42.38M 295K Sep/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024